San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium

December 07, 2016
3 min watch

VIDEO: Physicians must exercise caution with extended use of letrozole in hormone receptor–positive breast cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN ANTONIO — The extended use of letrozole conferred no survival benefit to postmenopausal women with hormone receptor–positive breast cancer, according to study results Terry P. Mamounas, MD, MPH, FACS, from the UF Health Cancer Center at Orlando Health, presented at San Antonio Breast Cancer Symposium.

However, the randomized, double blind, placebo-controlled clinical trial of extended letrozole — designed to evaluate the agent in women who completed 5 years of hormonal therapy with either an aromatase inhibitor or tamoxifen, followed by aromatase inhibitor — showed a 29% reduction in breast cancer-free interval and a 28% reduction in distant recurrence.

“We have to exercise caution as we discuss with our patients’ use of extended letrozole therapy,” Mamounas told HemOnc Today. “We need to look at the pros and cons. What is the risk for recurrence of the patient? What are significant comorbidities? What is the age of the patient? How did they tolerate the primary aromatase inhibitor for the first 5 years, and what is the bone mineral density? All of these factors figure into the potential decision of [whether to extend] therapy beyond 5 years or to stop at 5 years.” – by Kristie L. Kahl


Mamounas TP, et al. Abstract S1-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2016; San Antonio, Texas.